FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199180601> ?p ?o ?g. }

• W3199180601 abstract "Determining the efficacy, safety, and prognostic factors affecting overall survival (OS) among metastatic prostate cancer patients undergoing PSMA-targeted radioligand therapy (PRLT).In this retrospective study, from November 2016 and December 2019, 43 heavily pretreated (90.7% on 1st line androgen deprivation therapy (ADT), 53.5% on 2nd line ADT, 58.1% on docetaxel) metastatic prostate cancer patients with median age of 71 years (range: 51-88 years) were enrolled. Treatment cycles were repeated every 8 weeks (range: 6-12 weeks). To evaluate the biochemical response after each cycle, prostate specific antigen (PSA) levels were measured and analyzed according to the Prostate Cancer Working Group 3 (PCWG3) criteria cutoffs. Possible adverse events after therapy were retrospectively classified according to the Common Toxicity Criteria for Adverse Events (CTCAE) v.5.0. Kaplan-Meier and multivariable Cox proportional hazard regression analyses were used to identify factors associated with OS.A total of 112 cycles of PRLT with a median of 3 cycles (range: 1-6) and median administered activity per cycle of 6.29 GBq (range: 4.45-7.7 GBq) were used. PSA decline was observed in 65.1% of patients, and best PSA decline of ≥50% and ≥90% were achieved in 39.5% and 23.3% of patients, respectively. Major (grade III) anemia and thrombocytopenia occurred in 11.6% and 7% of patients, respectively. Median OS and median PSA progression-free survival were 52 and 20 weeks, respectively. In univariate analysis, baseline hemoglobin <11.2 g/dL, baseline platelets count ≥327,000/μL, PSA decline <20.94% after first cycle of therapy, Eastern Cooperative Oncology Group (ECOG) >2, baseline PSA ≥ 115 ng/mL, cumulative dose of 177Lu-PSMA <12.95 GBq, initial alkaline phosphatase ≥196.5 U/L, initial lactate dehydrogenase ≥380 U/L and superscan pattern in bone scintigraphy were associated with worse OS. In multivariable Cox regression analysis, higher baseline platelet count, lower baseline hemoglobin, superscan pattern, and lower cumulative dose of 177Lu-PSMA remained significant predictors of poor OS.PRLT with 177Lu-PSMA is well-tolerated and effective in metastatic prostate cancer patients who have no other treatment options available. The novel prognostic markers found in this study (high platelet count, superscan pattern) were associated with poor overall survival." @default.
• W3199180601 created "2021-09-27" @default.
• W3199180601 creator A5038394289 @default.
• W3199180601 creator A5042674189 @default.
• W3199180601 creator A5058140837 @default.
• W3199180601 creator A5062437542 @default.
• W3199180601 creator A5064710807 @default.
• W3199180601 date "2021-09-01" @default.
• W3199180601 modified "2023-10-02" @default.
• W3199180601 title "Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with 177Lu-PSMA-617: A single center study" @default.
• W3199180601 cites W2302508993 @default.
• W3199180601 cites W2532226140 @default.
• W3199180601 cites W2725251074 @default.
• W3199180601 cites W2768513671 @default.
• W3199180601 cites W2771847508 @default.
• W3199180601 cites W2780781461 @default.
• W3199180601 cites W2799931007 @default.
• W3199180601 cites W2804968346 @default.
• W3199180601 cites W2805106007 @default.
• W3199180601 cites W2808736367 @default.
• W3199180601 cites W2894392370 @default.
• W3199180601 cites W2937409539 @default.
• W3199180601 cites W2947722113 @default.
• W3199180601 cites W2969742213 @default.
• W3199180601 cites W2981468397 @default.
• W3199180601 cites W2990966824 @default.
• W3199180601 cites W3010388685 @default.
• W3199180601 cites W3035814258 @default.
• W3199180601 doi "https://doi.org/10.1016/j.remnie.2021.05.005" @default.
• W3199180601 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34526249" @default.
• W3199180601 hasPublicationYear "2021" @default.
• W3199180601 type Work @default.
• W3199180601 sameAs 3199180601 @default.
• W3199180601 citedByCount "3" @default.
• W3199180601 countsByYear W31991806012022 @default.
• W3199180601 countsByYear W31991806012023 @default.
• W3199180601 crossrefType "journal-article" @default.
• W3199180601 hasAuthorship W3199180601A5038394289 @default.
• W3199180601 hasAuthorship W3199180601A5042674189 @default.
• W3199180601 hasAuthorship W3199180601A5058140837 @default.
• W3199180601 hasAuthorship W3199180601A5062437542 @default.
• W3199180601 hasAuthorship W3199180601A5064710807 @default.
• W3199180601 hasConcept C121608353 @default.
• W3199180601 hasConcept C126322002 @default.
• W3199180601 hasConcept C126894567 @default.
• W3199180601 hasConcept C143998085 @default.
• W3199180601 hasConcept C144301174 @default.
• W3199180601 hasConcept C197934379 @default.
• W3199180601 hasConcept C207103383 @default.
• W3199180601 hasConcept C2777899217 @default.
• W3199180601 hasConcept C2778248108 @default.
• W3199180601 hasConcept C2780192828 @default.
• W3199180601 hasConcept C2781190966 @default.
• W3199180601 hasConcept C2781406297 @default.
• W3199180601 hasConcept C38180746 @default.
• W3199180601 hasConcept C44249647 @default.
• W3199180601 hasConcept C50382708 @default.
• W3199180601 hasConcept C71924100 @default.
• W3199180601 hasConceptScore W3199180601C121608353 @default.
• W3199180601 hasConceptScore W3199180601C126322002 @default.
• W3199180601 hasConceptScore W3199180601C126894567 @default.
• W3199180601 hasConceptScore W3199180601C143998085 @default.
• W3199180601 hasConceptScore W3199180601C144301174 @default.
• W3199180601 hasConceptScore W3199180601C197934379 @default.
• W3199180601 hasConceptScore W3199180601C207103383 @default.
• W3199180601 hasConceptScore W3199180601C2777899217 @default.
• W3199180601 hasConceptScore W3199180601C2778248108 @default.
• W3199180601 hasConceptScore W3199180601C2780192828 @default.
• W3199180601 hasConceptScore W3199180601C2781190966 @default.
• W3199180601 hasConceptScore W3199180601C2781406297 @default.
• W3199180601 hasConceptScore W3199180601C38180746 @default.
• W3199180601 hasConceptScore W3199180601C44249647 @default.
• W3199180601 hasConceptScore W3199180601C50382708 @default.
• W3199180601 hasConceptScore W3199180601C71924100 @default.
• W3199180601 hasFunder F4320322855 @default.
• W3199180601 hasLocation W31991806011 @default.
• W3199180601 hasLocation W31991806012 @default.
• W3199180601 hasOpenAccess W3199180601 @default.
• W3199180601 hasPrimaryLocation W31991806011 @default.
• W3199180601 hasRelatedWork W1980998207 @default.
• W3199180601 hasRelatedWork W1992247710 @default.
• W3199180601 hasRelatedWork W2529939135 @default.
• W3199180601 hasRelatedWork W2588988563 @default.
• W3199180601 hasRelatedWork W2770702948 @default.
• W3199180601 hasRelatedWork W2907060458 @default.
• W3199180601 hasRelatedWork W2912565296 @default.
• W3199180601 hasRelatedWork W2949755027 @default.
• W3199180601 hasRelatedWork W3111556708 @default.
• W3199180601 hasRelatedWork W3204029969 @default.
• W3199180601 isParatext "false" @default.
• W3199180601 isRetracted "false" @default.
• W3199180601 magId "3199180601" @default.
• W3199180601 workType "article" @default.